Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Circulating cytokine levels are elevated in many neuropathologies and may be a cause of the associated malaise and depression. Using a rat model, we demonstrate that sickness behaviors generated by microinjection of IL-1beta into the anterior hypothalamus are adopted by naive recipient animals following plasma transfer. We further show that neutralizing peripheral TNF by etanercept (a p75 TNF receptor/Fc fusion protein) prior to the IL-1beta microinjection inhibits certain IL-1beta-mediated sickness behaviors, such as the depression of open-field activity and reduced glucose consumption. IL-1beta-induced central lesions induce peripheral TNF as part of the acute-phase response, and this appears to be the principal target of the etanercept. Thus behavioral changes induced by CNS lesions may result from peripheral expression of cytokines that can be targeted with drugs which do not need to cross the blood-brain barrier to be efficacious.

Original publication

DOI

10.1016/j.nbd.2008.06.017

Type

Journal article

Journal

Neurobiol Dis

Publication Date

10/2008

Volume

32

Pages

125 - 132

Keywords

Animals, Behavior, Animal, Central Nervous System Diseases, Etanercept, Exploratory Behavior, Humans, Immunoglobulin G, Inflammation, Inflammation Mediators, Interleukin-1beta, Male, Rats, Rats, Wistar, Receptors, Tumor Necrosis Factor, Tumor Necrosis Factor-alpha